VA
VAL.LSE ValiRx plc
- Market cap
- GBX 2.24M
- P/E
- -
- P/B
- 0.72x
- ROE
- -95.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is VAL.LSE undervalued?
Graham numberThe Graham number of ValiRx plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ValiRx plc fundamental analysis
No fundamental analysis for ValiRx plc yet.
ValiRx plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ValiRx plc
ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperidone, which completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer; VAL201, a short peptide, which completed Phase I/II clinical trial for the treatment of prostate cancer; and VAL301, a peptide, which is in pre-clinical t…
Full company profileValiRx plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ValiRx plc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.60K | 49.8K | 31.4K | 5.20K |
| Gross Profit | -103K | -188K | -143K | -183K | -229K | -229K | -224K | -246K | -217K | -6.25K | -425K |
| Operating Income | -4.17M | -3.13M | -3.87M | -2.70M | -1.65M | -1.68M | -2.59M | -2.30M | -2.14M | -1.82M | -3.29M |
| EBITDA | -5.31M | -2.92M | -4.69M | -2.30M | -1.31M | -1.45M | -2.38M | -2.04M | -1.86M | -2.18M | -2.86M |
| Net Income | -4.75M | -3.14M | -4.37M | -2.43M | -1.47M | -1.55M | -2.41M | -2.04M | -1.92M | -2.23M | -2.98M |
| EPS | -10 | -2.60 | -1.19 | -0.34 | -0.04 | -0.02 | -0.03 | -0.02 | -0.01 | -0.01 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 4.96M | 4.94M | 4.23M | 3.60M | 4.94M | 3.52M | 3.98M | 3.13M | 4.26M | 2.63M | 2.77M |
| Total Liabilities | 2.59M | 1.78M | 1.20M | 1.38M | 182K | 110K | 150K | 227K | 346K | 235K | 121K |
| Shareholders' Equity | 2.35M | 3.18M | 3.12M | 2.35M | 4.91M | 3.60M | 4.05M | 3.22M | 4.32M | 2.86M | 3.13M |
| Cash & Short-term Investments | 561K | 701K | 373K | 0.00 | 1.85M | 594K | 1.14M | 175K | 1.56M | 792K | 971K |
| Total Debt | 1.29M | 390K | 314K | 199K | 71.1K | 58.7K | 37.7K | 22.1K | 11.9K | 1.40K | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.22M | -2.35M | -3.35M | -1.34M | -1.91M | -1.26M | -1.71M | -1.77M | -1.58M | -1.51M | -3.36M |
| Capital Expenditure | 387K | 280K | 324K | 397K | 93.3K | 2.00 | 5.00 | 306K | 38.2K | 13.6K | 0.00 |
| Free Cash Flow | -4.60M | -2.63M | -3.68M | -1.74M | -2.00M | -1.26M | -1.71M | -2.08M | -1.62M | -1.52M | -3.36M |
| Ratios | |||||||||||
| ROE | -202.1% | -98.7% | -139.8% | -103.1% | -29.9% | -43.0% | -59.4% | -63.3% | -44.4% | -78.2% | -95.3% |
| ROA | -95.7% | -63.6% | -103.1% | -67.3% | -29.7% | -43.9% | -60.5% | -65.1% | -44.9% | -84.8% | -107.9% |
| Net Profit Margin | - | - | - | - | - | - | - | -21,226.1% | -3,848.7% | -7,115.1% | -57,353.2% |
| Debt to Equity | 0.55x | 0.12x | 0.10x | 0.08x | 0.01x | 0.02x | 0.01x | 0.01x | 0.00x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ValiRx plc dividends
ValiRx plc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:125 on Apr 6, 2020.
Who owns ValiRx plc
- Insiders 8.77%
- Institutions 0.00%
- Public & others 91.23%
- Shares outstanding 1.32B
- Free float 789M
ValiRx plc company profile
- Company name
- ValiRx plc
- Ticker
- VAL.LSE
- ISIN
- GB00BLH13C52
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Fiscal year end
- December
- Address
- 20 Wenlock Road, London, United Kingdom, N1 7GU
- Phone
- 44 115 7840026
- Website
- valirx.com
About ValiRx plc
ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperidone, which completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer; VAL201, a short peptide, which completed Phase I/II clinical trial for the treatment of prostate cancer; and VAL301, a peptide, which is in pre-clinical trial for the treatment of endometriosis. It is also involved in the development of BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment of SARS-CoV2 infection; and CLX001, a peptide in a nanoparticle formulation for the treatment of triple negative breast cancer. The company was founded in 2006 and is based in London, the United Kingdom.
ValiRx plc management
5- Dr. Mark Edward Eccleston M.B.A., Ph.D.CEO, Member of Scientific & Commercial Advisory Board and Director · born 1971
- Mr. James Gerry Desler FCACFO, Company Secretary & Executive Director · born 1945
- Mr. Kumar NawaniHead of Operations
- Mr. Mark TreharneCorporate Development Manager
- Dr. Andrew CarnegieHead of Strategic Commercial Development